CA2323632A1 - Peptides de liaison de hla et leurs applications - Google Patents

Peptides de liaison de hla et leurs applications Download PDF

Info

Publication number
CA2323632A1
CA2323632A1 CA002323632A CA2323632A CA2323632A1 CA 2323632 A1 CA2323632 A1 CA 2323632A1 CA 002323632 A CA002323632 A CA 002323632A CA 2323632 A CA2323632 A CA 2323632A CA 2323632 A1 CA2323632 A1 CA 2323632A1
Authority
CA
Canada
Prior art keywords
peptide
peptides
falciparum
psm
prost
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002323632A
Other languages
English (en)
Inventor
Alessandro Sette
Ralph T. Kubo
John Sidney
Esteban Celis
Howard M. Grey
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2323632A1 publication Critical patent/CA2323632A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

L'invention concerne les appareils et les procédés permettant de sélectionner des peptides immunogènes et des compositions de peptides immunogènes capables de lier spécifiquement des glycoprotéines codées par un allèle HLA et induisant l'activation des lymphocytes T dans les lymphocytes limités par l'allèle. Les peptides sont utilisés pour provoquer une réaction immunitaire contre un antigène souhaité.
CA002323632A 1998-03-13 1998-03-13 Peptides de liaison de hla et leurs applications Abandoned CA2323632A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/005039 WO1999045954A1 (fr) 1998-03-13 1998-03-13 Peptides de liaison de hla et leurs applications

Publications (1)

Publication Number Publication Date
CA2323632A1 true CA2323632A1 (fr) 1999-09-16

Family

ID=22266589

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002323632A Abandoned CA2323632A1 (fr) 1998-03-13 1998-03-13 Peptides de liaison de hla et leurs applications

Country Status (5)

Country Link
EP (1) EP1064022A4 (fr)
JP (1) JP2002507397A (fr)
AU (1) AU6465598A (fr)
CA (1) CA2323632A1 (fr)
WO (1) WO1999045954A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102286075A (zh) * 2011-08-01 2011-12-21 中国人民解放军第三军医大学 乙肝病毒表面抗原的免疫显性hla-a*1101限制性ctl表位及其应用

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611713B2 (en) 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US9340577B2 (en) 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
US6291430B1 (en) 1997-09-12 2001-09-18 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en) 1997-09-12 2004-04-06 Ludwig Institute For Cancer Research Mage-A3 peptides presented by HLA class molecules
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6407063B1 (en) 1998-10-02 2002-06-18 Ludwig Institute For Cancer Research Tumor antigens and CTL clones isolated by a novel procedure
EP1117679B9 (fr) 1998-10-02 2010-07-07 Ludwig Institute For Cancer Research Antigenes tumoraux et clones de lymphocyte t cytotoxique (ctl) isoles grace a un nouveau procede
US6541214B1 (en) 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
GB9826143D0 (en) 1998-11-27 1999-01-20 Ludwig Inst Cancer Res Tumour rejection antigens
CN1334873A (zh) * 1998-12-01 2002-02-06 伊东恭悟 新型肿瘤抗原蛋白art－1及其肿瘤抗原肽
IT1309584B1 (it) * 1999-02-26 2002-01-24 San Raffaele Centro Fond Peptidi immunogenici derivati da mage-3 presentati da mhc di classeii e loro uso.
WO2001032193A1 (fr) * 1999-10-29 2001-05-10 Argonex Pharmaceuticals Peptides stimulant les lymphocytes t cytotoxiques, utilisables en prevention, traitement et diagnostic de melanome
EP1230268B1 (fr) * 1999-11-18 2009-10-14 Pharmexa Inc. Analogues heteroclites de classe i epitopes
EP1237564A4 (fr) * 1999-12-10 2005-05-04 Epimmune Inc Declenchement de reponses immunitaires cellulaires contre p53 au moyen de compositions d'acides nucleiques et de peptides
CA2393738A1 (fr) * 1999-12-10 2001-06-14 Epimmune Inc. Induction de reponses immunes cellulaires a her2/neu a l'aide de compositions renfermant des peptides et des acides nucleiques
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
AU2085001A (en) * 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
EP1244465A4 (fr) * 1999-12-21 2005-01-12 Epimmune Inc Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
US7462354B2 (en) 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
AU2001253029A1 (en) * 2000-03-30 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
CN1107681C (zh) * 2000-08-11 2003-05-07 中国科学院微生物研究所 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用
IL154415A0 (en) * 2000-08-14 2003-09-17 Corixa Corp Polynucleotides that encode her-2/neu polypeptides and pharmaceutical compositions containing the same
WO2002020053A1 (fr) * 2000-09-01 2002-03-14 Epimmune Inc. Peptides de fixation de hla et leurs utilisations
EP1195381A1 (fr) 2000-09-28 2002-04-10 Immusystems GmbH Epitopes du virus de l'hépatite C spécifiques à des lymphocytes T de type CD4+
JP4194365B2 (ja) 2000-10-31 2008-12-10 エムジーアイ ファーマ バイオロジックス インコーポレイテッド Ｃｙｐ１ｂ１核酸および使用の方法
JP2004535369A (ja) * 2001-03-01 2004-11-25 アメリカ合衆国 試薬およびワクチンとして使用するための免疫原性ｈｉｖペプチド
CN100589845C (zh) * 2001-03-07 2010-02-17 麦康公司 用于治疗癌症的抗新血管系统制剂
WO2003008537A2 (fr) * 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
EP1752160A3 (fr) * 2001-04-06 2007-05-30 Mannkind Corporation Sequences d'epitopes
US20040202654A1 (en) 2001-04-09 2004-10-14 Mayo Foundation For Medical Education & Research Methods and materials for cancer treatment
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7842480B2 (en) 2001-05-18 2010-11-30 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US7049413B2 (en) 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
CA2449715A1 (fr) * 2001-06-05 2002-12-12 The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services, Centers For Disea Peptides destines au diagnostic de chlamydophila pneumoniae et au vaccin contre chlamydophila pneumoniae
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
CA2357906A1 (fr) * 2001-09-28 2003-03-28 Institut Pasteur Identification de nouveaux epitopes de cd8 de proteines ayant des proprietes therapeutiques et immunologiques pour lutter contre les infections a vih
ES2358642T3 (es) * 2001-11-07 2011-05-12 Mannkind Corporation Vectores de expresión que codifican epítopos de antígenos y métodos para su diseño.
AU2002349543A1 (en) * 2001-12-10 2003-06-23 Kyogo Itoh Tumor antigens
JP2005522212A (ja) * 2002-04-05 2005-07-28 エピミューン インコーポレイテッド ヘテロクリティックアナログおよび関係する方法
EP1587837B1 (fr) * 2003-01-28 2012-06-13 Proscan RX Pharma Inc. Epitopes pour le diagnostic et le traitement du cancer de la prostate
JPWO2005007694A1 (ja) * 2003-07-16 2007-09-20 株式会社グリーンペプタイド ＨＥＲ２／ｎｅｕペプチドおよびその治療上の用途
AU2004281634B2 (en) * 2003-09-03 2011-01-27 Dendritherapeutics, Inc. Multiplex vaccines
KR20060087574A (ko) * 2003-09-22 2006-08-02 가부시키가이샤 그린 펩티드 Ｃ형 간염 바이러스 유래 펩티드
US7488793B2 (en) * 2003-09-22 2009-02-10 Ludwig Institute For Cancer Research Isolated peptide which binds to HLA-Cw*07 and uses thereof
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
EP1759323A2 (fr) 2004-04-21 2007-03-07 AlgoNomics N.V. Methode ed marquage par affinite de complexes de peptides/proteines
US20080249283A1 (en) * 2004-04-30 2008-10-09 Tomoya Miyakawa Hla-Binding Peptides, Precursors Thereof, Dna Fragments and Recombinant Vectors that Code for Those Peptide Sequences
WO2006035681A1 (fr) * 2004-09-27 2006-04-06 National University Corporation Tokyo Medical And Dental University EPITOPES ANTITUMORAUX Tax RESTREINTS EN HLA-A11
JP5116150B2 (ja) * 2005-09-07 2013-01-09 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
WO2007120834A2 (fr) 2006-04-13 2007-10-25 Peptimmune, Inc. Procédés de conception et de synthèse de compositions de polymères à séquence dirigée par expansion dirigée de la perméabilité épitopique
WO2008010010A1 (fr) * 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimisation et utilisation d'épitopes cryptiques hla-b7 en immunothérapie
AP3467A (en) 2007-10-16 2015-11-30 Peptimmune Inc Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes
JP5573679B2 (ja) * 2008-01-18 2014-08-20 アエラス グローバル ティービー ワクチン ファウンデーション マラリアワクチン組成物および細胞媒介免疫性を惹起する成分
US9249187B2 (en) 2009-01-28 2016-02-02 Epimmune Inc. Pan-DR binding polypeptides and uses thereof
US9265822B2 (en) * 2009-09-30 2016-02-23 Saint Louis University Peptides for inducing heterosubtypic influenza T cell responses
JP5930967B2 (ja) * 2010-09-08 2016-06-08 学校法人 埼玉医科大学 Ｃ型肝炎ウイルスリポソームワクチン
JP6130307B2 (ja) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム 再指向性免疫療法
WO2013036208A1 (fr) * 2011-09-09 2013-03-14 Agency For Science, Technology And Research Peptides activant la protéine p53
JP6385280B2 (ja) * 2012-01-20 2018-09-05 トーメ クロイツ、フェルナンド 自家癌細胞ワクチン
JP5999703B2 (ja) * 2013-01-09 2016-09-28 国立大学法人 東京医科歯科大学 ＨＬＡ−ＤＲ１拘束性Ｔａｘ特異的ＣＤ４＋Ｔ細胞エピトープ
ES2727552T3 (es) * 2015-02-18 2019-10-17 Hoffmann La Roche Inmunoconjugados para la inducción específica de la citotoxicidad de los linfocitos T frente a una célula diana
CN105037559B (zh) * 2015-08-17 2018-09-25 北京康爱瑞浩生物科技股份有限公司 治疗或预防乙肝的细胞毒性t淋巴细胞及其制备方法
GB201515321D0 (en) * 2015-08-28 2015-10-14 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers
TWI803835B (zh) 2015-08-28 2023-06-01 德商英麥提克生物技術股份有限公司 用於多種癌症之免疫治療的新穎胜肽、胜肽的組合物及支架
CA3048448A1 (fr) 2016-12-28 2018-07-05 Invvax, Inc. Vaccins contre la grippe
KR20200047660A (ko) * 2017-09-01 2020-05-07 다나-파버 캔서 인스티튜트 인크. 암의 치료를 위한 bcma 및 taci 항원에 특이적인 면역원성 펩타이드
EP3545967A1 (fr) * 2018-03-28 2019-10-02 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Plate-forme d'immunisation contre le cancer
CN113939527A (zh) * 2019-01-11 2022-01-14 新加坡科技研究局 Hla-a*11:01限制性乙型肝炎病毒(hbv)肽用于鉴别hbv特异性cd8+ t细胞的用途
CA3132435A1 (fr) * 2019-03-04 2020-09-10 University Health Network Recepteurs de lymphocytes t et leurs procedes d'utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020168374A1 (en) * 1992-08-07 2002-11-14 Ralph T. Kubo Hla binding peptides and their uses
CA2141960A1 (fr) * 1992-08-07 1994-02-17 Ralph T. Kubo Peptides fixateurs du hla et leurs usages
EP0914142B9 (fr) * 1996-03-11 2012-01-04 Epimmune Inc. Peptides presentant une affinite augmente pour au moins trois molecules de type hla-a3
BR9708220A (pt) * 1996-03-21 2000-01-04 Epimmune Inc Peptìdios de ligação hla-a2.1 e seus usos
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102286075A (zh) * 2011-08-01 2011-12-21 中国人民解放军第三军医大学 乙肝病毒表面抗原的免疫显性hla-a*1101限制性ctl表位及其应用

Also Published As

Publication number Publication date
EP1064022A1 (fr) 2001-01-03
AU6465598A (en) 1999-09-27
JP2002507397A (ja) 2002-03-12
WO1999045954A1 (fr) 1999-09-16
EP1064022A4 (fr) 2004-09-29

Similar Documents

Publication Publication Date Title
CA2323632A1 (fr) Peptides de liaison de hla et leurs applications
US7252829B1 (en) HLA binding peptides and their uses
EP1917970B1 (fr) Peptides se fixant au Hla et leurs utilisations
AU725550B2 (en) HLA binding peptides and their uses
EP0907370B1 (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
EP1263775A1 (fr) Peptides de liaison hla et utilisations de ces derniers
US20030152580A1 (en) Hla binding peptides and their uses
US20020177694A1 (en) Hla binding peptides and their uses
EP1089757B1 (fr) Peptides liant hla-a2 et leurs utilisations
WO2002020616A1 (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
EP1320377B1 (fr) Peptides de liaison aux hla et leurs utilisations
EP1767542B1 (fr) Peptides de fixation de HLA-A2.1 et leurs utilisation
EP1313505A1 (fr) Peptides de fixation de hla et leurs utilisations
JP2011139706A (ja) Ｈｌａ結合ペプチドおよびその使用方法
MXPA98007702A (en) Location peptides of locus hla-a2.1 and its u

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead